Volume 10,Issue 1
Fall 2025
Research Progress of Histamine and Its Receptors in Heart Diseases
Cardiovascular diseases are the leading cause of mortality and are increasing in prevalence. These diseases encompass a range of conditions affecting cardiac structure and function, impairing blood supply, myocardial activity, electrical conduction, and valve performance, posing significant health risks. Histamine, traditionally used in gastric secretion testing and desensitization therapies, along with its receptor antagonists, such as H1 (H1R) and H2 (H2R) receptors, has gained attention for its role in cardiac remodeling and heart failure. This review explores the involvement of histamine and its receptors in myocarditis, myocardial infarction, heart failure, and myocardial fibrosis. H1R and H2R contribute to cardiomyopathy, hypertension, and heart failure through mechanisms like immune cell modulation, inflammatory mediator release, and cardiomyocyte regulation. H3R and H4R potentially affect cardiac function by modulating neurotransmitter release and influencing sympathetic and parasympathetic activity. While the role of H4R remains unclear, its connection to immunity and inflammation suggests promising therapeutic potential. Histamine receptors represent critical factors in the progression of heart diseases, offering insights into their pathophysiology and therapeutic applications. Despite recent advances, further research is needed to clarify their specific mechanisms and therapeutic targets. Understanding histamine receptor pathways could pave the way for innovative strategies in preventing and treating heart diseases, addressing a significant global health challenge.
1. Writing Group of “Report on Cardiovascular Health and Diseases in China 2022,” 2023, Interpretation of the Key Points of the “Report on Cardiovascular Health and Diseases in China 2022.” Chinese Journal of Cardiology, 28(4): 297–312.
2. Li D, Chen J, Xie Y, et al., 2023, Research Progress of BAG3 Protein in Heart Disease. Chinese Pharmacological Bulletin, 39(11): 2017–2021.
3. Guimbal S, Cornuault L, Rouault P, et al., 2021, Mast Cells Are the Trigger of Small Vessel Disease and Diastolic Dysfunction in Diabetic Obese Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 41(4): e193–e207.
4. Tang H, Hou T, Zhou H, et al., 2024, Label-Free Cell Phenotypic Profiling of Histamine H4R Receptor and Discovery of Non-Competitive H4R Antagonist from Natural Products. Bioorganic Chemistry, 147: 107387.
5. Neumann J, Kirchhefer U, Dhein S, et al., 2021, The Roles of Cardiovascular H2-Histamine Receptors under Normal and Pathophysiological Conditions. Front Pharmacol, 12: 732842.
6. Stasiak A, Gola J, Kraszewska K, et al., 2018, Experimental Autoimmune Myocarditis in Rats and Therapeutic Histamine H1-H4 Receptor Inhibition. J Physiol Pharmacol, 69(6): 889–900.
7. Kotov G, Landzhov B, Stamenov N, et al., 2020, Changes in the Number of Mast Cells, Expression of Fibroblast Growth Factor-2 and Extent of Interstitial Fibrosis in Established and Advanced Hypertensive Heart Disease. Ann Anat, 232: 151564.
8. Potnuri AG, Allakonda L, Appavoo A, et al., 2018, Association of Histamine with Hypertension-Induced Cardiac Remodeling and Reduction of Hypertrophy with the Histamine-2-Receptor Antagonist Famotidine Compared with the Beta-Blocker Metoprolol. Hypertens Res, 41(12): 1023–1035.
9. Kondru SK, Potnuri AG, Allakonda L, et al., 2018, Histamine 2 Receptor Antagonism Elicits Protection Against Doxorubicin-Induced Cardiotoxicity in Rodent Model. Mol Cell Biochem, 441(1–2): 77–88.
10. Gergs U, Kirchhefer U, Bergmann F, et al., 2020, Characterization of Stressed Transgenic Mice Overexpressing H2-Histamine Receptors in the Heart. J Pharmacol Exp Ther, 374(3): 479–488.
11. McCaffrey SL, Lim G, Bullock M, et al., 2020, The Histamine 3 Receptor is Expressed in the Heart and its Activation Opposes Adverse Cardiac Remodeling in the Angiotensin I Mouse Model. Int J Mol Sci, 21(24): 9757.
12. Kupreishvili K, Fuijkschot WW, Vonk AB, et al., 2017, Mast Cells Are Increased in the Media of Coronary Lesions in Patients with Myocardial Infarction and May Favor Atherosclerotic Plaque Instability. J Cardiol, 69(3): 548–554.
13. Zhu B, Zhu X, Wang X, et al., 2022, Histamine Deficiency Promotes Myofibroblasts Transformation from HDC-Expressing CD11b+ Myeloid Cells in Injured Hearts Post Myocardial Infarction. J Cardiovasc Transl Res, 15(3): 621–634.
14. Zhang Z, Ding S, Wang Z, et al., 2022, Prmtl Upregulated by Hdc Deficiency Aggravates Acute Myocardial Infarction via NETosis. Acta Pharm Sin B, 12(4): 1840–1855.
15. Chen J, Hong T, Ding S, et al., 2017, Aggravated Myocardial Infarction-Induced Cardiac Remodeling and Heart Failure in Histamine-Deficient Mice. Sci Rep, 7: 44007.
16. Piera L, Olczak S, Kun T, et al., 2019, Disruption of Histamine/Hs Receptor Signal Reduces Collagen Deposition in Cultures Scar Myofibroblasts. J Physiol Pharmacol, 70(2): 239–247.
17. Hass C, Panda BP, Khanam R, et al., 2016, Histamine H3 Receptor Agonist Imetit Attenuated Isoproterenol-Induced Renin-Angiotensin System and Sympathetic Nervous System Overactivity in Myocardial Infarction of Rats. Drug Res (Stuttg), 66(6): 324–329.
18. Ferreira JP, Kraus S, Mitchell S, et al., 2019, World Heart Federation Roadmap for Heart Failure. Glob Heart, 14(3): 197–214.
19. Sato T, Aikawa T, 2022, The Role of Histamine H2 Receptor Antagonist in Heart Failure: A Potential Game-Changer? Eur J Prev Cardiol, 29(14):1852–1853.
20. Huang Y, Cai W, Yin S, et al., 2022, Histamine H2 Receptor Antagonist Exposure Was Related to Decreased All-Cause Mortality in Critical Ill Patients with Heart Failure: A Cohort Study. Eur J Prev Cardiol, 29(14): 1854–1865.
21. Leary PJ, Tedford RJ, Bluemke DA, et al., 2016, Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study. J Am Coll Cardiol, 67(13): 1544–1552.